Vanguard Group Inc. Purchases 700,243 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)

Vanguard Group Inc. raised its position in Capricor Therapeutics Inc (NASDAQ:CAPR) by 44.4% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 2,276,784 shares of the biotechnology company’s stock after acquiring an additional 700,243 shares during the period. Vanguard Group Inc. owned about 5.01% of Capricor Therapeutics worth $31,420,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. State Street Corp lifted its position in shares of Capricor Therapeutics by 27.8% in the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after purchasing an additional 111,291 shares in the last quarter. Black Diamond Financial LLC acquired a new position in Capricor Therapeutics during the fourth quarter valued at approximately $3,833,000. Charles Schwab Investment Management Inc. grew its stake in Capricor Therapeutics by 51.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company’s stock valued at $1,536,000 after purchasing an additional 37,868 shares in the last quarter. Oppenheimer & Co. Inc. increased its position in shares of Capricor Therapeutics by 52.4% during the 4th quarter. Oppenheimer & Co. Inc. now owns 104,231 shares of the biotechnology company’s stock worth $1,438,000 after purchasing an additional 35,823 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Capricor Therapeutics by 32.6% during the 4th quarter. Bank of New York Mellon Corp now owns 84,027 shares of the biotechnology company’s stock worth $1,160,000 after purchasing an additional 20,638 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Trading Up 4.6 %

Shares of NASDAQ CAPR opened at $9.29 on Monday. The business’s 50 day moving average is $12.71 and its 200-day moving average is $15.18. The firm has a market cap of $424.34 million, a P/E ratio of -8.76 and a beta of 4.65. Capricor Therapeutics Inc has a 1-year low of $3.52 and a 1-year high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.15. The firm had revenue of $11.13 million for the quarter, compared to analysts’ expectations of $9.87 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. Analysts forecast that Capricor Therapeutics Inc will post -1.21 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on CAPR. Cantor Fitzgerald reiterated an “overweight” rating and set a $30.00 price target on shares of Capricor Therapeutics in a report on Thursday, March 20th. HC Wainwright reissued a “buy” rating and set a $77.00 target price on shares of Capricor Therapeutics in a report on Monday, March 17th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.